EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CAR-T Cell Therapy for HIV Cure: Current Challenges, Advances and Future Directions

Monica-Daniela Padurariu-Covit iD, Costinela Georgescu, Mihaela Andreescu iD, Iulia Chiscop, Catalin Plesea-Condratovici iD, Manuela Arbune iD

Viruses · 14.12.2025 · 17 (12) · 1615

DOI: 10.3390/v17121615 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 14.12.2025. Verfasst von Monica-Daniela Padurariu-Covit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Medicine and Pharmacy Faculty, "Dunarea de Jos" University of Galati, 800008 Galati, Romania. Hauptthemen laut MEDLINE: HIV Infections, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Dunarea de Jos” University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiretroviral therapy (ART) effectively suppresses HIV replication but fails to eradicate latent reservoirs, leading to viral rebound after interruption. Chimeric antigen receptor (CAR) T-cell therapy offers a potential strategy to achieve durable remission. A systematic PubMed search (July 2020–June 2025) identified 253 studies on CAR-T therapy in HIV; 74 met inclusion criteria and were qualitatively analyzed. Preclinical data showed that CAR-T cells can recognize and eliminate infected cells, reach viral reservoirs, and persist long term, particularly when derived from hematopoietic stem cells. Dual-target and combination approaches with checkpoint inhibitors or latency-reversing agents enhanced antiviral efficacy. Early clinical studies confirmed safety and modest reservoir reduction. CAR-T cell therapy represents a promising step toward a functional HIV cure. Further optimization of design, integration with gene-editing technologies, and standardized clinical evaluation are required to confirm durable efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansHIV-1Virus LatencyAnimalsT-Lymphocytes

Stichwörter der Autor:innen

CAR-T cellsHIV curegene editing

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Clinical Medicine, Medicine and Pharmacy Faculty, "Dunarea de Jos" University of Galati, 800008 Galati, Romania.
  • Department of Hematology, Emergency County Hospital Sf. Apostol Andrei, 800578 Galati, Romania.
  • Department of Pharmaceutical Sciences, Medicine and Pharmacy Faculty, "Dunarea de Jos" University of Galati, 800008 Galati, Romania.
  • Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania.
  • Department of Hematology, Colentina Clinical Hospital, 050098 Bucharest, Romania.
  • Department of Clinical Surgery, "Dunarea de Jos" University of Galati, 800008 Galati, Romania.

ORCID-Profile: Monica-Daniela Padurariu-Covit, Mihaela Andreescu, Catalin Plesea-Condratovici, Manuela Arbune

Förderung

  • “Dunarea de Jos” University

Zitieren

APA

Padurariu-Covit, M. D., Georgescu, C., Andreescu, M., Chiscop, I., Plesea-Condratovici, C., & Arbune, M. (2025). CAR-T Cell Therapy for HIV Cure: Current Challenges, Advances and Future Directions. Viruses, 17(12), 1615. https://doi.org/10.3390/v17121615

Vancouver

Padurariu-Covit MD, Georgescu C, Andreescu M, Chiscop I, Plesea-Condratovici C, Arbune M. CAR-T Cell Therapy for HIV Cure: Current Challenges, Advances and Future Directions. Viruses. 2025;17(12):1615. doi:10.3390/v17121615

BibTeX
@article{PadurariuCovit2025,
  author = {Padurariu-Covit, Monica-Daniela and Georgescu, Costinela and Andreescu, Mihaela and Chiscop, Iulia and Plesea-Condratovici, Catalin and Arbune, Manuela},
  title = {CAR-T Cell Therapy for HIV Cure: Current Challenges, Advances and Future Directions},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {12},
  pages = {1615},
  doi = {10.3390/v17121615}
}
Kostenlos starten →